Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Niacin

Drug Profile

Niacin

Alternative Names: KS 01016; Niaspan; Nicotinic acid

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kos Pharmaceuticals
  • Developer AbbVie
  • Class Antihyperlipidaemics; Nicotinic acids; Peripheral vasodilators; Small molecules; Vitamins
  • Mechanism of Action GPR109A receptor agonists; GPR109B receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Lipid metabolism disorders

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 20 Sep 2013 First generic equivalent available in USA for Lipid disorders
  • 25 Mar 2013 Adverse events data from the phase III AIM-HIGH trial in Lipid metabolism disorders released
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top